Paris Diderot University study provided evidence that the benefits of early HCV detection and treatment outweigh the costs of treatment. To date most HCV testing is limited to elevated risk categories relays Jared Kaltwasser of MD Magazine.
The results were clear: “Universal screening led to the lowest prevalence of CHC and incidence of events, regardless of treatment initiation.” Kaltwasser noted that Nancy Reau, MD, an HCV specialist at Rush University Medical Center and a member of the American Liver Foundation’s National Medical Advisory Committee called out “that universal screening in the US would go a long way towards reducing stigma around HCV and identifying those in need of care.
Paris Diderot University
Lead Research/Investigator:Source: MD Magazine